1.5 Abstract in Rivista

1.5 Abstract in Rivista: [1767] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 461 a 480 di 1.767

Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets

2009-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S

Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials

2013-01-01 Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E

Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)

2008-01-01 Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S

Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors

2017-01-01 Bersanelli, M; Vaglio, A; Sverzellati, N; Galetti, M; Incerti, M; Parziale, R; Corrado, M; Cosenza, A; Ferri, L; Leonardi, F; Buti, S

Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study

2006-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negli, F; Buononato, M; Lazzarelli, S; Brighenti, M; Passalacqua, R

Phase III, randomised, multicentre, controlled trial of maintenance biotherapy for metastatic renal cell cancer with Interleukin-2 and Interferon-alpha-2a. A study of the Italian Oncological Group for Clinical Research (GOIRC)

2004-01-01 Passalacqua, R; Buzio, C; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Vaglio, A; Tomasello, Gl; Dalla Chiesa, M; Camisa, R; Caminiti, C

Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell’immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia

2015-01-01 Gandolfini, I; Piotti, G; Pilato, Fp; Buti, S; Bersanelli, M; Ferretti, S; Nizzoli, C; Galetti, M; Gnetti, L; Palmisano, A; Cremaschi, E; Delsante, M; Rocco, R; David, S; Maggiore, U

Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi

2006-01-01 Vaglio, A; Bongiovanni, C; Alberici, F; Manna, C; Passalacqua, R; Buti, S; David, S; Buzio, C

Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)

2007-01-01 Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R

Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)

2005-01-01 Passalacqua, R; Buzio, C; Dalla Chiesa, M; Camisa, R; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Tomasello, G; Caminiti, C

Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)

2010-01-01 Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S

Terapia di mantenimento con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) nel Carcinoma Renale Metastatico (CRm). Trial multicentrico, prospettico, randomizzato di fase III

2006-01-01 Vaglio, A; Passalacqua, R; Camisa, R; Dalla Chiesa, M; Labianca, R; Frassoldati, A; Porta, C; Buti, S; Caminiti, C; Bongiovanni, C; Alberici, F; Manna, C; David, S; Buzio, C

Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

2015-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G

Erythrocyte mean corpuscular volume change during pemetrexed treatment in advanced non small cell lung cancer patients

2012-01-01 Buti, S; Bordi, P; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, Sg; Pilotto, S; Camisa, R; Ardizzoni, A

Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

2012-01-01 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, Lm; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, G; Galligioni, E

Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder

2010-01-01 Brighenti, M; Liguigli, W; dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Lazzarelli, S; Poli, R; Donnini, M; Curti, A; Passalacqua, R; Potenzoni, D; Benecchi, L

Natural history of renal metastases to the pancreas: do not operate all and always?

2014-01-01 Burattini, L; Santoni, M; Conti, A; Partelli, S; Porta, C; Sternberg, Cn; Procopio, G; Bracarda, S; Basso, U; De Giorgi, U; Derosa, L; Rizzo, M; Ortega, C; Massari, F; Milella, M; Buti, S; Cerbone, L; Montironi, R; Falconi, M; Santini, D; Cascinu, S

Impact of low doses of immunotherapy (LDI) with interleukin-2 (IL-2) and interferon alpha (IFNA) in metastatic renal cell cancer (MRCC) patients with different prognostic risk

2006-01-01 Buti, S; Buzio, C; Vaglio, A; Bongiovanni, C; Alberici, F; Brighenti, M; Dalla Chiesa, M; Tomasello, G; Passalacqua, R

Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC)

2007-01-01 Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C

Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials

2011-01-01 Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crino, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, Ef

Titolo	Data di pubblicazione	Autore(i)
Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (MRCC): Bevacizumab (B) plus Immunotherapy (I) plus Chemotherapy (C) (BIC). Antitumor effects and variations of circulating T-regulatory cells (Treg) and other T lymphocytes subsets	1-gen-2009	Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Dalla Chiesa, M; Tomasello, G; Negri, F; Lazzarelli, S
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials	1-gen-2013	Caffo, O; Sava, T; Zustovich, F; Lodde, M; Sacco, C; Lo Re, G; Buti, S; Basso, U; Gamucci, T; Facchini, G; Perin, A; Segati, R; Russo, L; Veccia, A; Galligioni, E
Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC)	1-gen-2008	Passalacqua, R; Buti, S; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Mazza, G; Brighenti, M; Lazzarelli, S
Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors	1-gen-2017	Bersanelli, M; Vaglio, A; Sverzellati, N; Galetti, M; Incerti, M; Parziale, R; Corrado, M; Cosenza, A; Ferri, L; Leonardi, F; Buti, S
Dose-dense chemotherapy with Docetaxel, Cisplatin, folinic acid and 5-fluorouracil (TCAF DD) in metastatic gastric cancer (MGC): A feasibility study	1-gen-2006	Dalla Chiesa, M; Tomasello, G; Buti, S; Negli, F; Buononato, M; Lazzarelli, S; Brighenti, M; Passalacqua, R
Phase III, randomised, multicentre, controlled trial of maintenance biotherapy for metastatic renal cell cancer with Interleukin-2 and Interferon-alpha-2a. A study of the Italian Oncological Group for Clinical Research (GOIRC)	1-gen-2004	Passalacqua, R; Buzio, C; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Vaglio, A; Tomasello, Gl; Dalla Chiesa, M; Camisa, R; Caminiti, C
Primo caso di carcinoma vescicale sarcomatoide associato a BKV in paziente trapiantato di rene: possibile ruolo dell’immunoistochimica per BKV-TAg e p16 su citologia urinaria nella diagnosi precoce di neoplasia	1-gen-2015	Gandolfini, I; Piotti, G; Pilato, Fp; Buti, S; Bersanelli, M; Ferretti, S; Nizzoli, C; Galetti, M; Gnetti, L; Palmisano, A; Cremaschi, E; Delsante, M; Rocco, R; David, S; Maggiore, U
Sopravvivenza e risposta alla terapia in 139 pazienti affetti da Carcinoma Renale Metastatico (CRm) trattati con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) a basse dosi. Influenza del rischio prognostico rilevato alla diagnosi	1-gen-2006	Vaglio, A; Bongiovanni, C; Alberici, F; Manna, C; Passalacqua, R; Buti, S; David, S; Buzio, C
Gefitinib (G) plus Interleukin-2 (IL-2) in previously treated patients with advanced non-small-cell lung cancer (NSCLC)	1-gen-2007	Tomasello, G; Buti, S; Bosio, G; Stifani, I; Maestrelli, M; Brighenti, M; Porzio, R; Lazzarelli, S; Negri, F; Longarini, R; Passalacqua, R
Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)	1-gen-2005	Passalacqua, R; Buzio, C; Dalla Chiesa, M; Camisa, R; Porta, C; Labianca, R; Frassoldati, A; Buti, S; Pezzuolo, D; Tomasello, G; Caminiti, C
Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)	1-gen-2010	Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S
Terapia di mantenimento con Interleukina-2 (IL-2) ed Interferone Alfa (IFNα) nel Carcinoma Renale Metastatico (CRm). Trial multicentrico, prospettico, randomizzato di fase III	1-gen-2006	Vaglio, A; Passalacqua, R; Camisa, R; Dalla Chiesa, M; Labianca, R; Frassoldati, A; Porta, C; Buti, S; Caminiti, C; Bongiovanni, C; Alberici, F; Manna, C; David, S; Buzio, C
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)	1-gen-2015	Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; Di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Erythrocyte mean corpuscular volume change during pemetrexed treatment in advanced non small cell lung cancer patients	1-gen-2012	Buti, S; Bordi, P; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, Sg; Pilotto, S; Camisa, R; Ardizzoni, A
Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)	1-gen-2012	Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, Lm; Facchini, G; Barile, C; Gernone, A; De Vivo, R; Pappagallo, G; Galligioni, E
Feasibility of two sequential dose-dense regimens with cisplatin-gemcitabine-paclitaxel (CGP) and HD-MVAC in patients with metastatic transitional cell carcinoma of the bladder	1-gen-2010	Brighenti, M; Liguigli, W; dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Lazzarelli, S; Poli, R; Donnini, M; Curti, A; Passalacqua, R; Potenzoni, D; Benecchi, L
Natural history of renal metastases to the pancreas: do not operate all and always?	1-gen-2014	Burattini, L; Santoni, M; Conti, A; Partelli, S; Porta, C; Sternberg, Cn; Procopio, G; Bracarda, S; Basso, U; De Giorgi, U; Derosa, L; Rizzo, M; Ortega, C; Massari, F; Milella, M; Buti, S; Cerbone, L; Montironi, R; Falconi, M; Santini, D; Cascinu, S
Impact of low doses of immunotherapy (LDI) with interleukin-2 (IL-2) and interferon alpha (IFNA) in metastatic renal cell cancer (MRCC) patients with different prognostic risk	1-gen-2006	Buti, S; Buzio, C; Vaglio, A; Bongiovanni, C; Alberici, F; Brighenti, M; Dalla Chiesa, M; Tomasello, G; Passalacqua, R
Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the italian oncology group for clinical research (GOIRC)	1-gen-2007	Passalacqua, R; Buzio, C; Potenzoni, D; Buti, S; Labianca, R; Porta, C; Nastasi, P; Rondini, E; Camisa, R; Sabbatini, R; Artioli, F; Alberici, F; Bongiovanni, C; Pezzuolo, D; Caminiti, C
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials	1-gen-2011	Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crino, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, Ef

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 461 a 480 di 1.767

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext1735
reserved26
open6